L'intérêt à découvert pour Lexicon Pharmaceuticals donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Lexicon Pharmaceuticals. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock, Rapport sur les intérêts à découvert

LEXICON PHARMACEUTICALS INC

Lexicon Pharmaceuticals

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals Inc

U.S. stock futures fell on Monday after three consecutive days of decline on Friday. Futures of major benchmark indices were lower in premarket trading.
Stocks decline as investors await the day of incoming reciprocal tariffs on April 2nd. This is termed &#8220;Liberation Day&#8221; by U.S. President Donald Trump.
Goldman Sachs, in its recent note, predicted a <a href="https://www.benzinga.com/markets/equities/25/03/44554304/goldman-sachs-raises-us-recession-risk-to-35-expects-inflation-at-3-5-in-2025-amid-tariff-uncertainties-economist-mohamed-el-erian-highlights-stagflationary-twist">35% recession risk</a> and reciprocal tariffs that average 15% across all U.S. trading partners, although product and country exclusions could whittle the addition to the average U.S. tariff rate down to 9 percentage points.
The stock market ended the month of March and the first quarter on a rough note. As of Friday, the Nasdaq 100 index was 13.24% from its previous high. The S&amp;P 500 was 9.22% lower from its record level, and the Dow Jones was down 7.74% from its 52-week high.
With the 10-year Treasury yield at 4.63% and the 2-year at 3.88%, the CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a> shows markets pricing in an 82.1% likelihood of the Federal Reserve maintaining current interest rates through its May meeting. 
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-1.24%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.85%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.57%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-1.08%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, dropped in premarket on Friday. The SPY was down 0.71% to $551.70, while the QQQ declined 1.16% to $463.49, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
Most sectors on the S&amp;P 500 ended Friday in the red, with consumer discretionary, communication services, and information technology stocks posting the steepest losses. In contrast, utilities outperformed, closing the session higher despite broader market weakness.
Adding to market jitters, the Fed's preferred inflation gauge, the core Personal Consumption Expenditures price index, rose 2.8% year-over-year in February, exceeding expectations of 2.7%.
Investor anxiety was further fueled by the University of Michigan Survey of Consumers, which revealed a jump in 5-year forward inflation expectations to 4.1%, marking the highest level since February 1993.
In corporate earnings, AAR Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) shares plunged more than 16% after the company reported a third-quarter sales miss.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-2.70%</td>
<td>17,322.99</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-1.97%</td>
<td>5,580.94</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-1.69%</td>
<td>41,583.90</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-2.05%</td>
<td>2,023.27</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
As the date for &#8220;reciprocal tariffs&#8221; or "Liberation Day," as termed by President Trump, gets closer, Louis Navellier of Navellier &amp; Associates says that there is a lot for investors to be excited about in April.
&#8220;Overall, despite continued tariff distractions, after &#8216;Liberation Day,&#8217; I am expecting economic optimism to rise steadily in the upcoming months. Continued strong corporate earnings and lower interest rates are a powerful one-two punch that is expected to drop kick and propel economic growth dramatically higher,&#8221; he said.
However, Goldman Sachs has increased its U.S. recession probability from 20% to 35% in its recent note.
Christian Mueller-Glissmann, the leading asset allocation researcher at Goldman Sachs, has <a href="https://www.benzinga.com/25/03/44554923/goldman-sachs-warns-us-stocks-are-at-risk-of-further-declines-but-policy-pivot-from-trump-or-fed-could-stoke-reco">warned that the risk of further market correction</a> is still looming in the U.S. &#8220;The equity drawdown probability hasn&#8217;t peaked yet,&#8221; he said.
The factors supporting Goldman Sachs Research's view that the market correction has further to go include:
<ul>
<li>Its model's forecast has signaled heightened risk since January and has yet to indicate a peak in the likelihood of continued declines.</li>
</ul>
<ul>
<li>A weakening macroeconomic backdrop, combined with the equity drawdown, suggests that the market has not yet found a bottom.</li>
</ul>
<ul>
<li>The risk appetite indicator, which measures investor sentiment, remains above the ‘-2' threshold that historically signals a potential market reversal absent policy or economic shifts, indicating that a strong buying opportunity has not yet emerged.</li>
</ul>
<ul>
<li>The Magnificent Seven tech stocks, which play a key role in retail investor confidence, have experienced notable declines, and further weakness in these stocks could weigh on sentiment.</li>
</ul>
<ul>
<li>European and Chinese equities, which are currently outperforming the U.S., have historically led initially but ultimately followed the U.S. during broader market corrections, suggesting that a deeper U.S. downturn could pull global markets lower.</li>
</ul>
Mueller-Glissmann notes a key limitation of his equity drawdown model: it doesn't factor in policy shifts. "If President Trump or the Federal Reserve makes a major policy pivot, markets could recover much faster," he said.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures</a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on this week:
<ul>
<li>On Monday, March&#8217;s Chicago Business Barometer (PMI) will be released by 9:45 a.m. ET.</li>
</ul>
<ul>
<li>On Tuesday, Richmond Federal Reserve President Thomas Barkin will speak at 9:00 a.m. ET.</li>
</ul>
<ul>
<li>March&#8217;s S&amp;P final U.S. manufacturing PMI will be out by 9:45 a.m. ET.</li>
</ul>
<ul>
<li>February&#8217;s construction spending, job openings, and March&#8217;s ISM manufacturing data will be released by 10:00 a.m. ET and the time for auto sales data is yet to be determined.</li>
</ul>
<ul>
<li>On Wednesday, March&#8217;s ADP employment data will be out by 8:15 a.m. ET.</li>
</ul>
<ul>
<li>February&#8217;s factory orders data will be released at 10:00 a.m. ET.</li>
</ul>
<ul>
<li>Fed Governor Adriana Kugler will speak at 4:30 p.m. ET.</li>
</ul>
<ul>
<li>On Thursday, the initial jobless claims data for the week ending March 29 and February&#8217;s U.S. trade deficit data will be released by 8:30 a.m. ET.</li>
</ul>
<ul>
<li>March&#8217;s S&amp;P final U.S. services PMI and ISM services will be announced between 9:45 and 10:00 a.m. ET.</li>
</ul>
<ul>
<li>Fed Vice Chairman Philip Jefferson will speak at 12:30 p.m., and Fed Governor Lisa Cook will speak at 2:30 p.m. ET.</li>
</ul>
<ul>
<li>On Friday, March&#8217;s U.S. employment report, unemployment rate, and hourly wages data will be out by 8:30 a.m. ET.</li>
</ul>
<ul>
<li>Fed Chairman Jerome Powell will speak at 11:25 a.m. ET.</li>
</ul>
<ul>
<li>Fed Governor Michael Barr will speak at noon, and Fed Governor Christopher Waller will speak at 12:45 p.m. ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>PVH Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) fell 0.66% in premarket on Monday ahead of its earnings after the closing bell. Analysts expect a quarterly earnings of $3.22 per share on revenue of $2.34 million.</li>
</ul>
<ul>
<li>Progress Software Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRGS#NASDAQ">PRGS</a>) tumbled 0.31% as Wall Street expects it to report a quarterly earnings of $1.06 per share on revenue of $235.63 million after the closing bell.</li>
</ul>
<ul>
<li>Loar Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOAR#NYSE">LOAR</a>) declined 1.64% ahead of its earnings before the opening bell. Analysts expect a quarterly earnings of 10 cents per share on revenue of $102.54 million.</li>
</ul>
<ul>
<li>Babcock &amp; Wilcox Enterprises Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BW#NYSE">BW</a>) was up 1.27% as Wall Street expects it to report a quarterly loss of 1 cent per share on revenue of $213.07 million after the closing bell.</li>
</ul>
<ul>
<li>Xos Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOS#NASDAQ">XOS</a>) jumped 9.01% as its 2024 revenue surged to $56 million, compared to $44.5 million in 2023. The company delivered 297 units in 2024, up from 283 units in the previous year.</li>
</ul>
<ul>
<li>Acuren Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIC#NYSE">TIC</a>) slumped 37.78% after a revenue miss and reported a $105.5 million Successor Net Loss for 2024, mainly due to one-time transaction costs. Combined Adjusted EBITDA rose 11.5% to $186.7 million, with margins improved to 17.0% from 15.9% in 2023.</li>
</ul>
<ul>
<li>Treasure Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGL#NASDAQ">TGL</a>) surged 47.50% as it announced plans to develop and deploy an advanced AI cloud infrastructure in Malaysia capable of supporting trillion-parameter models, last week.</li>
</ul>
<ul>
<li>Lexicon Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) was up 1.38% as it signed an exclusive global license deal with Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) for a first-in-class oral non-incretin drug for obesity and metabolic disorders. The agreement includes up to $1 billion in potential payments, with $75 million upfront and in near-term milestones</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading higher in the early New York session by 0.74% to hover around $69.87 per barrel.
Gold Spot US Dollar advanced 1.24% to hover around $3,122.41 per ounce. Its fresh record high stood at $3,127.88 per ounce. The U.S. Dollar Index spot was lower by 0.05% at the 103.997 level.
Asian markets closed on a lower note on Monday. China&#8217;s CSI 300, India's S&amp;P BSE Sensex, Hong Kong's Hang Seng, South Korea's Kospi, Japan's Nikkei 225, and Australia's ASX 200 index declined. European markets were also lower in early trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44554923/goldman-sachs-warns-us-stocks-are-at-risk-of-further-declines-but-policy-pivot-from-trump-or-fed-could-stoke-reco">Goldman Sachs Warns US Stocks &#8216;Are At Risk Of Further Declines,&#8217; But Policy Pivot From Trump Or Fed Could Stoke Recovery</a></li>
</ul>
Photo courtesy: Shutterstock

Analyst Color

Asia

Earnings

Earnings Beats

Earnings Misses

Equities

Government

Macro Economic Events

Macro Notification

Market Summary

News

Regulations

Bonds

Broad U.S. Equity ETFs

Guidance

Emerging Markets

Eurozone

Futures

Commodities

Forex

Treasuries

Economics

Federal Reserve

Pre-Market Outlook

Markets

Analyst Ratings

ETFs

General

LOAR

LXRX

PRGS

US Stocks Likely To Open Lower After 3-Day Fall: 'Equity Drawdown Probability Hasn't Peaked Yet,' Says Goldman Sachs Analyst

As uncertainties surrounding trade policies, fresh recession fears, and persistent inflation kept the markets on tenterhooks throughout the past week, a handful of small-caps defied the odds by posting significant gains. 
These stocks, all part of the Russell 2000 index, have market caps lower than $2 billion and have rallied between 11% and 60% over the past week, while the broader index witnessed a pullback of 2.5%. Let us explore these stocks and the various factors contributing to their resilience.
<h2 class="wp-block-heading">1. Lexicon Pharmaceuticals</h2>
The three-decades-old Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) posted a phenomenal 58% rally last week, after announcing that it was entering into an exclusive licensing agreement with Danish pharma giant, Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>). 
The agreement pertains to Lexicon&#8217;s LX9851, an oral non-incretin development candidate for treating obesity and other metabolic disorders. It provides Novo with exclusive rights to develop, manufacture, and commercialize the drug worldwide.
The deal is set to generate Lexicon up to $1 billion in milestone and royalty payments over the coming years, prompting a quick &#8216;Buy&#8217; rating from Joseph Pantginis of H.C. Wainwright, alongside <a href="https://www.benzinga.com/insights/analyst-ratings/25/03/44542815/what-6-analyst-ratings-have-to-say-about-lexicon-pharmaceuticals">several other analysts</a>. 
See Also: <a href="https://www.benzinga.com/markets/equities/25/03/44554008/wall-street-on-edge-futures-slide-ahead-of-trumps-liberation-day-tariff-shock">Wall Street On Edge: Futures Slide Ahead of Trump&#8217;s &#8216;Liberation Day&#8217; Tariff Shock</a>
<h2 class="wp-block-heading">3. LightWave Logic </h2>
LightWave Logic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LWLG#NASDAQ">LWLG</a>) develops photonic devices and electro-optic polymer materials for fiber-optic communications, all of which play a critical role in semiconductor foundries and AI data centers. 
Last week, the company announced its Process Design Kit (PDK) which is now commercially available after already being implemented at two major foundries. This <a href="https://www.benzinga.com/insights/movers/25/03/44547240/12-information-technology-stocks-moving-in-fridays-after-market-session">led the stock to pop 19% on Friday</a>, ending the week up by 10%. A picks-and-shovels play, the stock is expected to maintain momentum as the AI race heats up.
<h2 class="wp-block-heading">3. Argan Inc</h2>
Argan Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGX#NYSE">AGX</a>), a Maryland-based engineering, procurement, and construction company that&#8217;s been around since the early-60s. The stock popped nearly 20% on Friday, ending the week up by 11%, following its <a href="https://www.benzinga.com/25/03/44536628/argan-posts-upbeat-results-joins-kulr-technology-abacus-global-management-w-r-berkley-and-other-big-stocks-moving-higher-on-friday">spectacular fourth-quarter earnings performance</a>.
The company reported $232 million in revenue during the fourth quarter, up 40% year-over-year, and a profit of $31.4 million, or $2.22 per share, up 150% year-over-year, while handily beating analyst estimates.
Argan&#8217;s performance is largely owing to its power industry services business, with revenues growing 65% to $196 million, and contributing to its massive order backlog at $1.4 billion, up 80% from the prior year. The company is riding the demand for natural gas-fired power plants to fuel the endless new AI data centers.
Benzinga's Edge Rankings highlight strong momentum and growth ranking For Argan in the 97th and 85th percentile, respectively. Curious how Lexicon Pharmaceuticals stacks up? <a href="https://www.benzinga.com/quote/AGX">Click here</a> to uncover its growth and momentum scores
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/AGX"><img loading="lazy" decoding="async" width="1024" height="178" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31010543/Screenshot-2025-03-31-at-10.35.05-AM-1024x178.png" alt="" class="wp-image-848423" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31010543/Screenshot-2025-03-31-at-10.35.05-AM-1024x178.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31010543/Screenshot-2025-03-31-at-10.35.05-AM-300x52.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31010543/Screenshot-2025-03-31-at-10.35.05-AM-768x134.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31010543/Screenshot-2025-03-31-at-10.35.05-AM.png 1436w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Image via Shutterstock
Read More:
<ul>
<li><a href="https://www.benzinga.com/tech/25/03/44552954/inside-apples-silent-revolution-ai-doctors-nutrition-tech-and-a-new-retail-boss">Inside Apple&#8217;s Silent Revolution—AI Doctors, Nutrition Tech, And A New Retail Boss</a></li>
</ul>

Small Cap

LWLG

While Wall Street Panicked, These 3 Hidden Small-Caps Exploded Last Week — One Surging A Jaw-Dropping 60%

During the last three months, 6 analysts shared their evaluations of Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>), revealing diverse outlooks from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Lexicon Pharmaceuticals, presenting an average target of $3.83, a high estimate of $6.00, and a low estimate of $1.00. This current average has decreased by 26.35% from the previous average price target of $5.20. 
<img src="https://www.benzinga.com/files/images/story/2025/1743184842_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A clear picture of Lexicon Pharmaceuticals's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$4.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Yasmeen Rahimi</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$6.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$4.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Roanna Ruiz</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$1.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$4.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$4.00</td>
<td>$4.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Lexicon Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Lexicon Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Lexicon Pharmaceuticals's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of Lexicon Pharmaceuticals's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/LXRX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Lexicon Pharmaceuticals analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Lexicon Pharmaceuticals Better</h2>
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
<h3>Lexicon Pharmaceuticals: A Financial Overview</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Lexicon Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 3682.62%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Lexicon Pharmaceuticals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -127.16%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Lexicon Pharmaceuticals's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -20.81%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -10.9%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a high debt-to-equity ratio of 0.74, Lexicon Pharmaceuticals faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 6 Analyst Ratings Have To Say About Lexicon Pharmaceuticals

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) with a Buy and maintains $4 price target.

Price Target

Reiteration

HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $4 Price Target

<h3>Gainers</h3>
<ul>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares moved upwards by 105.9% to $9.7 during Friday's regular session. The company's market cap stands at $15.9 million. </li>
<li>Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) shares rose 78.39% to $0.62. The company's market cap stands at $224.1 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) stock rose 40.92% to $5.51. The market value of their outstanding shares is at $113.0 million. </li>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) stock rose 29.3% to $0.56. The market value of their outstanding shares is at $14.0 million. As per the press release, Q4 earnings came out today. </li>
<li>23andMe Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ME#NASDAQ">ME</a>) shares moved upwards by 14.24% to $0.88. The market value of their outstanding shares is at $23.5 million. </li>
<li>Prelude Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLD#NASDAQ">PRLD</a>) shares increased by 14.09% to $0.78. The company's market cap stands at $42.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares decreased by 72.5% to $0.04 during Friday's regular session. </li>
<li>Milestone Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIST#NASDAQ">MIST</a>) shares declined by 60.37% to $0.89. The market value of their outstanding shares is at $47.5 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares fell 51.28% to $0.02. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares decreased by 29.73% to $1.6. The company's market cap stands at $18.4 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares declined by 27.68% to $2.64. The company's market cap stands at $1.7 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock fell 26.02% to $25.8. The market value of their outstanding shares is at $335.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

DBVT

LGMK

MIST

PRLD

PRTG

SNSE

STSS

VERO

12 Health Care Stocks Moving In Friday's Intraday Session

U.S. stocks traded lower this morning, with the Nasdaq Composite falling around 100 points on Friday.
Following the market opening Friday, the Dow traded down 0.24% to 42,198.64 while the NASDAQ fell 0.57% to 17,701.94. The S&amp;P 500 also fell, dropping, 0.36% to 5,672.68.
Check This Out: <a href="https://www.benzinga.com/25/03/44513063/jim-cramer-stryker-is-a-good-company-likes-this-utilities-stock">Jim Cramer: Stryker Is A &#8216;Good&#8217; Company, Says He Likes This Utilities Stock</a>
Leading and Lagging Sectors Utilities shares jumped by 0.6% on Friday.
In trading on Friday, consumer discretionary shares fell by 1.4%.
Top Headline
The Federal Reserve&#8217;s preferred inflation gauge rose more than anticipated in February, underscoring the bumpy road back to the 2% target and throwing cold water on expectations for imminent interest rate cuts.
According to data released Friday by the Bureau of Economic Analysis, the Personal Consumption Expenditures (PCE) price index increased by 2.5% year-over-year, matching both the previous reading and economist forecasts of 2.5%. On a monthly basis, headline PCE rose 0.3%, in line with estimates.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Portage Biotech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares shot up 170% to $12.79 after the company reported new data for PORT-7 at the 2025 European Lung Cancer Congress.</li>
<li>Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>)got a boost, surging 83% to $0.6359 after the company announced an exclusive license agreement with Novo Nordisk for LX9851.</li>
<li>DBV Technologies S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) shares were also up, gaining 43% to $5.79 after the company announced up to $307 million in financing to advance the Viaskin Peanut program.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Milestone Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIST#NASDAQ">MIST</a>) shares dropped 64% to $0.7997 after the company received a letter from the FDA for its new drug applicationfFor CARDAMYST nasal spray.</li>
<li>Shares of XTI Aerospace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTIA#NASDAQ">XTIA</a>) were down 48% to $1.2689 after the company priced its public offering at $1.36 per share.</li>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) was down, falling 41% to $3.18. On Thursday, Wolfspeed announced the appointment of Robert Feurle as CEO, effective May 1, 2025.</li>
</ul>
Commodities In commodity news, oil traded down 0.1% to $69.82 while gold traded up 0.5% at $3,106.80.
Silver traded up 0.5% to $35.255 on Friday, while copper rose 0.5% to $5.1440.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 declined 0.3%, Germany's DAX 40 fell 0.5% and France's CAC 40 dipped 0.6%. Spain's IBEX 35 Index fell 0.5%, while London's FTSE 100 rose 0.1%.
Asia Pacific Markets
Asian markets closed lower on Friday, with Japan's Nikkei 225 falling 1.80%, China's Shanghai Composite Index declining 0.67%, Hong Kong's Hang Seng Index dipping 0.65% and India's BSE Sensex falling 0.25%.
Economics
<ul>
<li>The Personal Consumption Expenditures (PCE) price index increased by 2.5% year-over-year, matching both the previous reading and economist forecasts of 2.5%. On a monthly basis, headline PCE rose 0.3%, in line with estimates.</li>
<li>Personal spending rose 0.4% month-over-month in February after a 0.3% contraction in January, but missing expectations for a 0.5% increase.</li>
<li>Personal income growth accelerated to 0.8%, above January&#8217;s 0.7% and well beyond the 0.4% estimate.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44534992/how-to-earn-500-a-month-from-pvh-stock-ahead-of-q4-earnings">How To Earn $500 A Month From PVH Stock Ahead Of Q4 Earnings</a></li>
</ul>
Photo: Shutterstock

Intraday Update

Trading Ideas

WOLF

XTIA

Nasdaq Down 100 Points; Federal Reserve's Favorite Inflation Gauge Increases More Than Expected

Lexicon Pharmaceuticals Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) stock is trading higher on Friday.
Penny stock Lexicon Pharmaceuticals entered into an exclusive license agreement with Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) on Friday for LX9851, a first-in-class, oral non-incretin development candidate in obesity and <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">associated metabolic disorders</a>.
Under the terms of the agreement, Novo Nordisk obtains an exclusive, worldwide license to develop, manufacture, and commercialize LX9851 in all indications.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/03/44077892/lexicon-pharmaceuticals-lxrx-stock-is-down-whats-going-on" rel="noreferrer noopener">Lexicon Pharmaceuticals (LXRX) Stock Is Down: What&#8217;s Going On?</a>
Lexicon will be responsible for completing the agreed-upon Investigational New Drug (IND) application-enabling activities for LX9851.
Novo Nordisk will file the IND and all further development, manufacturing, and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44533398/lexicon-pharmaceuticals-announces-exclusive-license-agreement-with-novo-nordisk-for-lx9851" rel="noreferrer noopener">commercialization of LX9851</a>.
Lexicon is eligible to receive upfront and near-term milestone payments of up to $75 million. In total, Lexicon will be eligible to receive $1 billion in upfront and potential development, regulatory and sales milestone payments. Lexicon is also entitled to tiered royalties on net sales of LX9851.
LX9851, discovered and developed by Lexicon, is a potent and selective oral small molecule inhibitor of Acyl-CoA Synthetase 5 (ACSL5)​.
ACSL5 plays a key role in the metabolic pathway, which regulates fat accumulation and energy balance.
Additionally, LX9851 may activate the ileal brake mechanism leading to increased satiety by delaying gastric emptying and suppressing appetite. Preclinical in vivo efficacy data presented at <a href="https://www.globenewswire.com/Tracker?data=OnqucjvUItjNyIg8Mt_EdS5E-HsBhpGCKna9AsgPMqz_3pXJBPSIDGMamdOk_9q0umGChZhm4tPcFJu2ihpA4sIxTNjAtT_aPDbbLe6FYHr-irCJNKUHmfOvId9qNdtIqFsqcc1AipR6qQqC_Mp7Y_eIYeJ-37LfxZC6JtS4lUTTW9qTCSPmdNXIVCrDkHED1yDRb3KggXMmyG6JL9t8Hi6-cRmOkiJGAcK0zGbUi-g=" target="_blank" rel="noreferrer noopener">Obesity Week 2024</a> show that LX9851, when combined with Novo Nordisk&#8217;s semaglutide, significantly reduced weight, food intake and fat mass compared to semaglutide alone.
Separately, LX9851 mitigated weight regain and had positive effects on liver steatosis when introduced after semaglutide discontinuation.
Price Action: LXRX stock is up 97.4% at $0.69 during the premarket session at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/25/03/44523216/microsoft-plans-proprietary-ai-to-power-business-software-and-reduce-openai-dependence-report" target="_blank" rel="noreferrer noopener">Microsoft Plans Proprietary AI To Power Business Software And Reduce OpenAI Dependence: Report</a></li>
</ul>
Photo: Shutterstock

Biotech

Large Cap

Health Care

Contracts

Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk

<h3>Gainers</h3>
<ul>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) stock rose 158.8% to $12.19 during Friday's pre-market session. The market value of their outstanding shares is at $20.0 million. </li>
<li>Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) stock rose 106.53% to $0.72. The company's market cap stands at $259.5 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) shares moved upwards by 61.12% to $6.3. The company's market cap stands at $129.2 million. </li>
<li>Prelude Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLD#NASDAQ">PRLD</a>) shares increased by 17.14% to $0.8. The company's market cap stands at $44.0 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock moved upwards by 15.59% to $0.6. </li>
<li>Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) stock increased by 15.51% to $1.02. The company's market cap stands at $16.9 million. As per the press release, Q4 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Milestone Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIST#NASDAQ">MIST</a>) stock fell 61.8% to $0.86 during Friday's pre-market session. The company's market cap stands at $45.8 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares declined by 24.12% to $0.04. The market value of their outstanding shares is at $1.0 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock decreased by 24.0% to $0.19. The company's market cap stands at $1.3 million. </li>
<li>Dermata Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRMA#NASDAQ">DRMA</a>) shares decreased by 20.43% to $1.13. The company's market cap stands at $6.1 million. </li>
<li>Sera Prognostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERA#NASDAQ">SERA</a>) stock fell 20.26% to $3.11. The company's market cap stands at $117.1 million. </li>
<li>Design Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGN#NASDAQ">DSGN</a>) shares declined by 16.23% to $3.51. The company's market cap stands at $199.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DRMA

DSGN

IRIX

PTIX

RNAZ

SERA

12 Health Care Stocks Moving In Friday's Pre-Market Session

WIIM

Lexicon Pharmaceuticals shares are trading higher after the company announced an exclusive license agreement with Novo Nordisk for LX9851.

Lexicon Pharmaceuticals Enters Exclusive License Agreement With Novo Nordisk For LX9851, Potentially Worth Up To $1B In Milestone Payments; Company Sees &nbsp;Upfront And Near-term Milestone Payments Of Up To $75M
&nbsp;
&nbsp;

Lexicon Pharmaceuticals Enters Exclusive License Agreement With Novo Nordisk For LX9851, Potentially Worth Up To $1B In Milestone Payments; Company Sees  Upfront And Near-term Milestone Payments Of Up To $75M

Piper Sandler analyst Yasmeen Rahimi maintains Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) with a Overweight and lowers the price target from $10 to $6.

Piper Sandler Maintains Overweight on Lexicon Pharmaceuticals, Lowers Price Target to $6

Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $3.25, a high estimate of $4.00, and a low estimate of $1.00. Highlighting a 18.75% decrease, the current average has fallen from the previous average price target of $4.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1741352446_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of Lexicon Pharmaceuticals's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$4.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Roanna Ruiz</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$1.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$4.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$4.00</td>
<td>$4.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Lexicon Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Lexicon Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Lexicon Pharmaceuticals's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Lexicon Pharmaceuticals's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LXRX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Lexicon Pharmaceuticals analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Lexicon Pharmaceuticals's Background</h2>
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
<h3>Unraveling the Financial Story of Lexicon Pharmaceuticals</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Positive Revenue Trend: Examining Lexicon Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 980.25% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Lexicon Pharmaceuticals's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -3703.49% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Lexicon Pharmaceuticals's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -30.97%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Lexicon Pharmaceuticals's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -18.66%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.57, caution is advised due to increased financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Lexicon Pharmaceuticals Stock

Needham analyst Joseph Stringer reiterates Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) from Hold to Hold.

Needham Reiterates Hold on Lexicon Pharmaceuticalsto Hold

Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.12) by 25 percent. This is a 55 percent increase over losses of $(0.20) per share from the same period last year. The company reported quarterly sales of $26.55 million which beat the analyst consensus estimate of $6.48 million by 309.78 percent. This is a 3.68K percent increase over sales of $702.00 thousand the same period last year.

Lexicon Pharmaceuticals Q4 EPS $(0.09) Beats $(0.12) Estimate, Sales $26.55M Beat $6.48M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Priority Tech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTH#NASDAQ">PRTH</a>) is expected to report quarterly earnings at $0.07 per share on revenue of $227.93 million. 
• KVH Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KVHI#NASDAQ">KVHI</a>) is projected to report quarterly loss at $0.07 per share on revenue of $28.12 million. 
• Dingdong (Cayman) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDL#NYSE">DDL</a>) is projected to report quarterly earnings at $0.00 per share on revenue of $793.81 million. 
• Seanergy Maritime Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIP#NASDAQ">SHIP</a>) is likely to report quarterly earnings at $0.43 per share on revenue of $40.15 million. 
• Dynagas LNG Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLNG#NYSE">DLNG</a>) is estimated to report quarterly earnings at $0.28 per share on revenue of $38.34 million. 
• ALX Oncology Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>) is likely to report earnings for its fourth quarter. 
• Ranpak Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACK#NYSE">PACK</a>) is expected to report quarterly loss at $0.02 per share on revenue of $100.41 million. 
• VerifyMe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRME#NASDAQ">VRME</a>) is likely to report quarterly loss at $0.04 per share on revenue of $8.21 million. 
• Xeris Biopharma Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XERS#NASDAQ">XERS</a>) is likely to report quarterly loss at $0.05 per share on revenue of $60.00 million. 
• Stevanato Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STVN#NYSE">STVN</a>) is projected to report quarterly earnings at $0.20 per share on revenue of $352.00 million. 
• Phathom Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAT#NASDAQ">PHAT</a>) is projected to report quarterly loss at $1.07 per share on revenue of $26.04 million. 
• John Wiley &amp; Sons (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLYB#NYSE">WLYB</a>) is likely to report earnings for its third quarter. 
• John Wiley &amp; Sons (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLY#NYSE">WLY</a>) is projected to report quarterly earnings at $0.45 per share on revenue of $401.10 million. 
• Turning Point Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPB#NYSE">TPB</a>) is projected to report quarterly earnings at $0.75 per share on revenue of $102.27 million. 
• Macy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) is estimated to report quarterly earnings at $1.91 per share on revenue of $7.84 billion. 
• Burlington Stores (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) is likely to report quarterly earnings at $3.76 per share on revenue of $3.29 billion. 
• Kroger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) is expected to report quarterly earnings at $1.09 per share on revenue of $34.87 billion. 
• Mind Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNMD#NASDAQ">MNMD</a>) is projected to report earnings for its fourth quarter. 
• JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) is estimated to report quarterly earnings at $0.80 per share on revenue of $45.16 billion. 
• Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $12.42 million. 
• Cracker Barrel Old (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBRL#NASDAQ">CBRL</a>) is likely to report quarterly earnings at $0.41 per share on revenue of $836.96 million. 
• GMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMS#NYSE">GMS</a>) is projected to report quarterly earnings at $1.40 per share on revenue of $1.29 billion. 
• Superior Industries Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUP#NYSE">SUP</a>) is expected to report quarterly loss at $0.60 per share on revenue of $300.28 million. 
• Evogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) is expected to report quarterly loss at $0.73 per share on revenue of $3.62 million. 
• Marex Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRX#NASDAQ">MRX</a>) is expected to report quarterly earnings at $0.61 per share on revenue of $370.82 million. 
• ProFrac Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACDC#NASDAQ">ACDC</a>) is likely to report quarterly loss at $0.23 per share on revenue of $498.50 million. 
• Toro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTC#NYSE">TTC</a>) is expected to report quarterly earnings at $0.63 per share on revenue of $1.01 billion. 
• Sunrise Realty Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUNS#NASDAQ">SUNS</a>) is projected to report earnings for its fourth quarter. 
• Vanguard Extended Duration Treasury ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDV#NYSE">EDV</a>) is projected to report earnings for its fourth quarter. 
• BrightSpring Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTSG#NASDAQ">BTSG</a>) is likely to report quarterly earnings at $0.20 per share on revenue of $2.95 billion. 
• America's Car-Mart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMT#NASDAQ">CRMT</a>) is expected to report quarterly earnings at $0.17 per share on revenue of $273.39 million. 
• BlackSky Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKSY#NYSE">BKSY</a>) is projected to report quarterly loss at $0.26 per share on revenue of $34.23 million. 
• Distribution Solns Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGR#NASDAQ">DSGR</a>) is likely to report quarterly earnings at $0.33 per share on revenue of $463.80 million. 
• Hippo Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIPO#NYSE">HIPO</a>) is projected to report quarterly earnings at $0.07 per share on revenue of $98.75 million. 
• Polestar Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) is expected to report quarterly loss at $0.15 per share on revenue of $634.04 million. 
• Canadian Natural Res (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNQ#NYSE">CNQ</a>) is likely to report quarterly earnings at $0.95 per share on revenue of $8.90 billion. 
• Real Brokerage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REAX#NASDAQ">REAX</a>) is likely to report quarterly loss at $0.05 per share on revenue of $282.20 million. 
• Myers Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYE#NYSE">MYE</a>) is likely to report quarterly earnings at $0.10 per share on revenue of $203.10 million. 
• TORM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRMD#NASDAQ">TRMD</a>) is expected to report quarterly earnings at $0.74 per share on revenue of $280.86 million. 
• BJ's Wholesale Club (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>) is expected to report quarterly earnings at $0.86 per share on revenue of $5.30 billion. 
<h3>Companies Reporting After The Bell</h3>
• Samsara (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IOT#NYSE">IOT</a>) is expected to report quarterly earnings at $0.07 per share on revenue of $335.35 million. 
• Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $6.48 million. 
• DXP Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXPE#NASDAQ">DXPE</a>) is estimated to report quarterly earnings at $0.86 per share on revenue of $431.00 million. 
• Reliance Global Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELI#NASDAQ">RELI</a>) is projected to report earnings for its fourth quarter. 
• Cherry Hill Mortgage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHMI#NYSE">CHMI</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $2.37 million. 
• Research Frontiers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REFR#NASDAQ">REFR</a>) is expected to report earnings for its fourth quarter. 
• Silvercrest Asset Mgmt Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAMG#NASDAQ">SAMG</a>) is likely to report quarterly earnings at $0.30 per share on revenue of $31.97 million. 
• Xtant Medical Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/XTNT#AMEX">XTNT</a>) is projected to report quarterly loss at $0.02 per share on revenue of $31.80 million. 
• Cango (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CANG#NYSE">CANG</a>) is likely to report earnings for its fourth quarter. 
• ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) is projected to report quarterly earnings at $0.69 per share on revenue of $717.27 million. 
• Comstock (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LODE#AMEX">LODE</a>) is projected to report quarterly loss at $0.20 per share on revenue of $700 thousand. 
• Marchex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHX#NASDAQ">MCHX</a>) is likely to report quarterly loss at $0.02 per share on revenue of $12.01 million. 
• GEN Restaurant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GENK#NASDAQ">GENK</a>) is likely to report quarterly loss at $0.03 per share on revenue of $49.77 million. 
• CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) is estimated to report quarterly loss at $0.13 per share on revenue of $13.53 million. 
• Atea Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVIR#NASDAQ">AVIR</a>) is estimated to report earnings for its fourth quarter. 
• National CineMedia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCMI#NASDAQ">NCMI</a>) is projected to report quarterly earnings at $0.31 per share on revenue of $83.72 million. 
• Fidus Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDUS#NASDAQ">FDUS</a>) is estimated to report quarterly earnings at $0.52 per share on revenue of $36.66 million. 
• Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) is estimated to report quarterly loss at $1.61 per share on revenue of $5.00 million. 
• IDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDT#NYSE">IDT</a>) is expected to report earnings for its second quarter. 
• Smith &amp; Wesson Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWBI#NASDAQ">SWBI</a>) is likely to report quarterly earnings at $0.02 per share on revenue of $119.46 million. 
• Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) is estimated to report quarterly loss at $0.51 per share on revenue of $45.92 million. 
• Serve Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>) is expected to report quarterly loss at $0.13 per share on revenue of $254 thousand. 
• Clarus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLAR#NASDAQ">CLAR</a>) is expected to report quarterly earnings at $0.09 per share on revenue of $69.03 million. 
• Guidewire Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) is expected to report quarterly earnings at $0.52 per share on revenue of $285.83 million. 
• Elutia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELUT#NASDAQ">ELUT</a>) is likely to report quarterly loss at $0.25 per share on revenue of $6.40 million. 
• MeridianLink (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLNK#NYSE">MLNK</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $78.53 million. 
• Asure Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASUR#NASDAQ">ASUR</a>) is estimated to report quarterly earnings at $0.17 per share on revenue of $30.82 million. 
• BigBear.ai Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>) is projected to report quarterly loss at $0.05 per share on revenue of $54.17 million. 
• Traeger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COOK#NYSE">COOK</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $164.62 million. 
• Domo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOMO#NASDAQ">DOMO</a>) is projected to report quarterly loss at $0.16 per share on revenue of $78.00 million. 
• AerSale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASLE#NASDAQ">ASLE</a>) is estimated to report quarterly earnings at $0.08 per share on revenue of $91.78 million. 
• Guild Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GHLD#NYSE">GHLD</a>) is projected to report quarterly earnings at $0.37 per share on revenue of $272.74 million. 
• Hudson Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HDSN#NASDAQ">HDSN</a>) is expected to report quarterly loss at $0.02 per share on revenue of $37.96 million. 
• a.k.a. Brands Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AKA#NYSE">AKA</a>) is projected to report quarterly loss at $0.23 per share on revenue of $154.49 million. 
• American Outdoor Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AOUT#NASDAQ">AOUT</a>) is likely to report quarterly earnings at $0.10 per share on revenue of $56.78 million. 
• Funko (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNKO#NASDAQ">FNKO</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $285.79 million. 
• Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) is likely to report quarterly loss at $0.07 per share on revenue of $3.95 million. 
• American Public Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APEI#NASDAQ">APEI</a>) is estimated to report quarterly earnings at $0.62 per share on revenue of $161.78 million. 
• El Pollo Loco Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOCO#NASDAQ">LOCO</a>) is projected to report quarterly earnings at $0.14 per share on revenue of $115.83 million. 
• Noodles (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDLS#NASDAQ">NDLS</a>) is likely to report quarterly loss at $0.14 per share on revenue of $121.36 million. 
• Potbelly (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBPB#NASDAQ">PBPB</a>) is projected to report quarterly earnings at $0.05 per share on revenue of $115.23 million. 
• Loma Negra Cia Industria (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOMA#NYSE">LOMA</a>) is estimated to report quarterly loss at $0.10 per share on revenue of $221.13 million. 
• Granite Ridge Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRNT#NYSE">GRNT</a>) is expected to report quarterly earnings at $0.13 per share on revenue of $104.93 million. 
• Invesco Dorsey Wright Industrials Momentum ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRN#NASDAQ">PRN</a>) is likely to report quarterly loss at $0.47 per share on revenue of $5.92 million. 
• Profound Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROF#NASDAQ">PROF</a>) is expected to report quarterly loss at $0.34 per share on revenue of $5.92 million. 
• Gap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) is projected to report quarterly earnings at $0.38 per share on revenue of $4.07 billion. 
• Hewlett Packard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) is projected to report quarterly earnings at $0.50 per share on revenue of $7.82 billion. 
• HASHICORP INC CL A (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCP#NASDAQ">HCP</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $175.71 million. 
• ACCESS Newswire (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ACCS#AMEX">ACCS</a>) is likely to report quarterly earnings at $0.23 per share on revenue of $7.38 million. 
• Information Servs Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/III#NASDAQ">III</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $57.62 million. 
• Full House Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLL#NASDAQ">FLL</a>) is likely to report quarterly loss at $0.19 per share on revenue of $75.78 million. 
• Willdan Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLDN#NASDAQ">WLDN</a>) is expected to report quarterly earnings at $0.57 per share on revenue of $145.00 million. 
• Broadcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) is expected to report quarterly earnings at $1.47 per share on revenue of $14.62 billion. 
• Ero Copper (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ERO#NYSE">ERO</a>) is estimated to report earnings for its fourth quarter. 
• Velocity Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEL#NYSE">VEL</a>) is estimated to report quarterly earnings at $0.48 per share on revenue of $42.70 million. 
• Cooper Companies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>) is expected to report quarterly earnings at $0.92 per share on revenue of $980.87 million. 
• Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) is expected to report quarterly earnings at $4.01 per share on revenue of $62.61 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACCS

ACDC

ALXO

AOUT

APEI

ARCT

ASLE

ASUR

AVGO

AVIR

BBAI

BlackSky Technology Inc. Class A Common Stock

BKSY

BTSG

BURL

CANG

CBRL

CHMI

CLAR

COOK

COST

CRMT

CTMX

DCTH

DLNG

DOMO

DSGR

DXPE

ELUT

EVGN

FDUS

FNKO

GENK

GEVO

GHLD

GRNT

GWRE

HDSN

HIPO

KVHI

LOCO

LODE

LOMA

MCHX

MLNK

MNMD

MODV

MOLN

NCMI

NDLS

PACK

PBPB

PHAT

PowerShares Dynamic Industrials Sector Portfolio

PROF

PRTH

PSNY

REAX

REFR

RELI

SAMG

SERV

SHIP

STVN

SUNS

SWBI

TRMD

VRME

WLDN

WLYB

XERS

XTNT

Earnings Scheduled For March 6, 2025

Lexicon Pharmaceuticals shares are trading lower after the company announced topline results from its PROGRESS Phase 2b study of pilavapadin. Despite the study not meeting statistical significance in its primary endpoint, the 10 mg dose showed clear clinical benefits over placebo.

Lexicon Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) shares are trading lower by 42% to 40 cents Monday morning. The company earlier <a href="https://www.benzinga.com/pressreleases/25/03/g44073239/lexicon-pharmaceuticals-announces-topline-results-from-phase-2b-progress-study-evaluating-pilavapa">announced topline results</a> from its PROGRESS Phase 2b study evaluating pilavapadin (LX9211) for diabetic peripheral neuropathic pain.
What To Know: The study confirmed that a 10 mg daily dose achieved meaningful pain reduction with improved tolerability, making it the optimal dose for Phase 3 trials. Unlike the prior RELIEF-DPN-1 study, PROGRESS eliminated the high initial loading dose, improving patient tolerability while maintaining efficacy.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44076200/bitcoin-ethereum-xrp-consolidate-after-trump-strategic-reserve-announcement">Bitcoin, Ethereum, XRP Consolidate After Trump Strategic Reserve Announcement</a>
The company says, despite the study not meeting statistical significance in its primary endpoint, the 10 mg dose showed clear clinical benefits over placebo. Adverse events, primarily dizziness and nausea, were less severe than in previous trials, with the 10 mg dose being well-tolerated. 
Lexicon's CEO, Mike Exton, emphasized pilavapadin's potential to become the first new oral non-opioid treatment for neuropathic pain in 20 years. Full study results will be published in a peer-reviewed journal.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, LXRX has a 52-week high of $2.83 and a 52-week low of $0.62.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44075328/eric-trump-says-timing-of-strategic-bitcoin-xrp-cardano-reserve-announcement-was-a-win-for" target="_blank" rel="noreferrer noopener">Eric Trump Says Timing Of Strategic Bitcoin, XRP, Cardano Reserve Announcement Was A ‘Win&#8217; For Retail Investors</a></li>
</ul>

Lexicon Pharmaceuticals (LXRX) Stock Is Down: What's Going On?

Press Releases

Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain

Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)

Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025

Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851

Emerging Tech Quartet – PRSO, LXRX, PRTG, RNAZ – Drive Breakthroughs Across Defense, Obesity, Oncology, and RNA Therapeutics

Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

PRSO

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Comments

Lexicon Pharmaceuticals

Intérêt court

Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL